Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 2

Status

Completed 5Terminated 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Conditions

Advanced Cancer 6Neoplasms 2Melanoma 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Skin Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Malignancies Multiple 1Lung Neoplasms 1Head and Neck Neoplasms 1Advanced Gastric Cancer 1

Interventions

Nivolumab 19Ipilimumab 9linrodostat 6relatlimab 4Pemetrexed 4Paclitaxel 4Carboplatin 4ARRY-334543 4Docetaxel 3regorafenib 2anlotinib 2abemaciclib 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Gemcitabine 2Cyclophosphamide 2Capecitabine 26-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2vorolanib 1trametinib 1tislelizumab 1sargramostim 1ralimetinib 1prexasertib 1palifosfamide lysine 1p38 Mitogen-Activated Protein Kinases 1mirdametinib 1lirilumab 1indibulin 1gedatolisib 1fluzoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Cancer × linrodostat × Clear all
NCT03459222 2026-04-06

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Bristol-Myers Squibb

Phase 1/2 Completed
229 enrolled 21 charts

Advanced Cancer

NCT02996110 2022-12-19

FRACTION-RCC

Bristol-Myers Squibb

Phase 2 Completed
182 enrolled 23 charts

Advanced Cancer

NCT03335540 2022-09-26

ADVISE

Bristol-Myers Squibb

Phase 1 Completed
20 enrolled

Advanced Cancer

NCT03792750 2022-02-28

A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors

Bristol-Myers Squibb

Phase 1/2 Completed
12 enrolled 26 charts

Advanced Cancer

NCT02750514 2021-03-22

FRACTION-Lung

Bristol-Myers Squibb

Phase 2 Terminated
295 enrolled 21 charts

Advanced Cancer

NCT03192943 2019-04-01

A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors

Bristol-Myers Squibb

Phase 1 Completed
11 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡